Oxford Genetics to leverage CRISPR platform under new agreement

Novartis’ BLA accepted for gene replacement therapy
Credit: Shutterstock.com/ Sergey Nivens

Oxford Genetics has secured a multi-million-pound contract with a multi-billion-dollar global ecommerce provider of reagents and tools to the research and clinical community.

As part of the agreement, Oxford Genetics will leverage its high throughput automated genomic engineering platform for CRISPR modification of mammalian cell lines.

CEO Ryan Cawood said: “This contract highlights Oxford Genetics’ commitment to providing the highest quality cell line engineering services to its global customer base and continuing to add value to their operations.

“We have moved away from manual processing, which is the norm in this market, in favour of automated, scalable platforms.

“This approach means we are well positioned to deliver the large number of custom-engineered cell lines per year that the global market is forecast to need.”

Headquartered in Oxford, UK, Oxford Genetics is a synthetic biology company dedicated to developing and delivering technologies and services to its customers that will help to change the gene editing industry.

The company’s use of automation allows it to develop new and innovative solutions, the latest of which is its mammalian CRISPR cell line engineering platform.